Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Rani Therapeutics Holdings (RANI – Research Report), Puma Biotechnology (PBYI – Research Report) and BeiGene (BGNE – Research Report).
Rani Therapeutics Holdings (RANI)
H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Rani Therapeutics Holdings today and set a price target of $20.00. The company’s shares closed last Tuesday at $2.95, close to its 52-week low of $2.56.
According to TipRanks.com, Kapoor has 0 stars on 0-5 stars ranking scale with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Rani Therapeutics Holdings with a $20.25 average price target.
See Insiders’ Hot Stocks on TipRanks >>
Puma Biotechnology (PBYI)
H.C. Wainwright analyst Edward White reiterated a Buy rating on Puma Biotechnology today and set a price target of $8.00. The company’s shares closed last Tuesday at $2.98.
According to TipRanks.com, White has currently 0 stars on a ranking scale of 0-5 stars, with an average return of
Currently, the analyst consensus on Puma Biotechnology is a Hold with an average price target of $5.00.
BeiGene (BGNE)
In a report released today, David Li from Bank of America Securities reiterated a Hold rating on BeiGene, with a price target of $212.00. The company’s shares closed last Tuesday at $208.86.
Li has an average return of
According to TipRanks.com, Li is ranked #8195 out of 8562 analysts.
BeiGene has an analyst consensus of Strong Buy, with a price target consensus of $262.64.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on RANI:
- Rani Therapeutics initiates Phase 1 study of RT-111
- Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)
- Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies
- Rani Therapeutics to Participate in September Investor Conferences
- Rani Therapeutics price target lowered to $17 from $19 at BofA
